Oceňování 2020, 13(1):53-64 | DOI: 10.18267/j.ocenovani.246
Specifics of valuation in the drug development sector
- 1 Ing. Jakub Mašek - doktorand; Katedra financí a oceňování podniku, Fakulta financí a účetnictví, Vysoká škola ekonomická v Praze
- 2 Ing. Radana Šmídová, Ph.D. - odborný asistent; Katedra financí a oceňování podniku, Fakulta financí a účetnictví, Vysoká škola ekonomická v Praze
The aim of this article is to analyse specific aspects of valuation in drug development sector. The article is reacting to recent development around SARS-CoV-2 pandemic and aims to provide valuable information to professionals from investment community interested in opportunities in pharma and biotech sector. Consequently article involves deep analysis of the industry, its dynamics and industry specifics that are determining for company valuation.
Keywords: Valuation; Pharmacy; Biotech; Intangible assets; Patent protection; Clinical trials
Grants and funding:
Článek je zpracován jako jeden z výstupů výzkumného projektu Fakulty financí a účetnictví VŠE, který je realizován v rámci institucionální podpory VŠE IP100040.
JEL classification: G39
Published: October 7, 2020 Show citation
References
- VILLIGER, Ralph a Boris BOGDAN. Valuation in Life Sciences: A Practical Guide. Berlin, Germany: Springer-Verlag Berlin and Heidelberg GmbH & Co., 2010. ISBN 9783642108198.
- WOUTERS, Olivier J. a Jeroen LUYTEN. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2020, 323(9), 844-853. DOI: 10.1001/jama.2020.1166.
Go to original source... - SINGHAL, Shubham a Erica COE. The next imperatives for US healthcare. McKinsey & Company [online]. 2016 [cit. 2018-05-14]. Dostupné z: https://healthcare.mckinsey.com/sites/default/files/MCK_NextImperatives.pdf
- 2018 Global health care outlook: The evolution of smart health care. Deiloitte [online]. 2018 [cit. 2018-05-14]. Dostupné z: https://www2.deloitte.com/global/en/pages/life-sciences-andhealthcare/articles/global-health-care-sector-outlook.html
- World Preview 2017: Outlook to 2022. Evaluate Pharma [online] 2017 [cit. 2018-05-14]. Dostupné z: http://info.evaluategroup.com/rs/607-YGS364/images/WP17.pdf Go to original source...
- Pharma 2020: Challenging business models. PWC | Global [online]. 2009 [cit. 2018-05-14]. Dostupné z: https://www.pwc.com/gx/en/pharma-lifesciences/pdf/challenge.pdf
- Pharmaceuticals and Life Sciences: Industry Trends. Stratégy& Part of the PwC network | Global [online]. 2017 [cit. 2018-05-14]. Dostupné z: https://www.strategyand.pwc.com/media/file/2017-Pharmaceuticals-and-LifeSciences-Industry-Trends.pdf Go to original source...
- Europe's healthcare systems face reform to meet growing challenges. United Europe [online]. 2015 [cit. 2018-05-14]. Dostupné z: https://www.unitedeurope.eu/2015/03/europes-healthcare-systems-face-reform-to-meet-growingchallenges
- SEGAL, T. Biotech vs Pharmaceutical company. Investopedia [online]. 2017 [cit. 2018-05-14]. Dostupné z: https://www.investopedia.com/ask/answers/033115/what-difference-betweenbiotechnology-company-and-pharmaceutical-company.asp
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.